Investment activity is surging in Asia’s biotech sector. Eight companies have filed on the Hong Kong Stock Exchange with two seeking dual listings. NASDAQ firms Ocular, Ovid, and Palisade have completed raises, while venture capitalists back startups Crystalys, Star, and Cartography. Industry analysts note the rapid evolution of China's biotech deal dynamics, signaling sustained capital inflows and expansion opportunities.